FARN — Faron Pharmaceuticals Oy Share News
0.000.00%
Last trade - 00:00- £203.26m
- £210.97m
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
AnnouncementUpdated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients
AnnouncementREG - AIM - AIM Notice - 10/10/2025
AnnouncementREG - AIM - AIM Notice - 06/10/2025
AnnouncementREG - AIM - AIM Notice - 04/06/2025
AnnouncementREG - Faron Pharma. Oy - FDA Grants Orphan Drug Designation
AnnouncementREG - Faron Pharma. Oy - Notice of Annual General Meeting
AnnouncementREG - Faron Pharma. Oy - Positive EMA Opinion on Orphan Drug Designation
AnnouncementREG - Faron Pharma. Oy - Financial Statement 1 January to 31 December 2024
AnnouncementREG - Faron Pharma. Oy - Annual Report 2024 published
AnnouncementREG - Faron Pharma. Oy - Notice of Financial Statement and Annual Report
AnnouncementREG - Faron Pharma. Oy - Holding(s) in Company
AnnouncementREG - Faron Pharma. Oy - Change of Broker
AnnouncementREG - Faron Pharma. Oy - Holding(s) in Company
AnnouncementREG - Faron Pharma. Oy - Results of Oversubscribed Placing
AnnouncementREG - Faron Pharma. Oy - Proposed Issue and Placing
AnnouncementRCS - Faron Pharma. Oy - Final Patient Identified for BEXMAB Phase II Study
AnnouncementREG - Faron Pharma. Oy - Faron’s Financial Calendar for 2025
AnnouncementRCS - Faron Pharma. Oy - Faron presents BEXMAB data at ASH Annual Meeting
Announcement